416 related articles for article (PubMed ID: 18425954)
1. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R; Macleod A; Ives N; Stowe R; Counsell C
Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KD
Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
[TBL] [Abstract][Full Text] [Related]
8. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
[TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
[TBL] [Abstract][Full Text] [Related]
14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Ives NJ; Stowe RL; Marro J; Counsell C; Macleod A; Clarke CE; Gray R; Wheatley K
BMJ; 2004 Sep; 329(7466):593. PubMed ID: 15310558
[TBL] [Abstract][Full Text] [Related]
16. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002261. PubMed ID: 10908540
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
